Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Signs Deal to Sell $2.2M in Stock, Warrants

NEW YORK (GenomeWeb) – Biocept today said that it has signed an agreement to sell $2.2 million in stock and warrants to Hong Kong-based investment group Ally Bridge LB Healthcare Master Fund Limited.

Under the terms of the deal, Ally Bridge will receive roughly 1.5 million common shares of Biocept stock, along with warrants to buy approximately 1.4 million additional shares, at a combined offering price of $1.50. The warrants have a per-share exercise price of $1.50, are exercisable immediately, and will expire in five years from the date of issuance.

Biocept also said that it is in discussions about leveraging its liquid biopsy platform in China with Ally Bridge affiliates. Specific details about these discussions were not disclosed.

During morning trading on the Nasdaq, shares of Biocept were unchanged at $1.39.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.